

## JAST (Journal of Animal Science and Technology) TITLE PAGE

Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
<b>Article Type</b>	Research Article
<b>Article Title (within 20 words without abbreviations)</b>	<i>Weissella confusa</i> WiKim51 (Wilac D001) fermented mycelium extract attenuates joint inflammation through PGE2 regulation in collagen-induced arthritis rats
<b>Running Title (within 10 words)</b>	Joint inflammation-attenuating effects of <i>Weissella confusa</i> WiKim51 fermented mycelium extract
<b>Author</b>	Jae-Young Kim <sup>1,2</sup> , Yi Hyun Choi <sup>1</sup> , Sang Min Park <sup>3</sup> , Ji Ye Mok <sup>3</sup> , Jeong Hyun Seo <sup>3</sup> and Sae Hun Kim <sup>1,2*</sup>
<b>Affiliation</b>	<sup>1</sup> College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea <sup>2</sup> Institute of Life Science and Natural Resources, Korea University, Seoul 02841, Republic of Korea <sup>3</sup> Pharmsville Co., Ltd., Seoul 06642, Republic of Korea
<b>ORCID (for more information, please visit <a href="https://orcid.org">https://orcid.org</a>)</b>	Jae-Young Kim ( <a href="https://orcid.org/0000-0003-1937-9535">https://orcid.org/0000-0003-1937-9535</a> ) Yi Hyun Choi ( <a href="https://orcid.org/0009-0006-0513-1503">https://orcid.org/0009-0006-0513-1503</a> ) Sang Min Park ( <a href="https://orcid.org/0000-0002-5599-233X">https://orcid.org/0000-0002-5599-233X</a> ) Ji Ye Mok ( <a href="https://orcid.org/0009-0009-2542-0785">https://orcid.org/0009-0009-2542-0785</a> ) Jeong Hyun Seo ( <a href="https://orcid.org/0000-0002-9197-4550">https://orcid.org/0000-0002-9197-4550</a> ) Sae Hun Kim ( <a href="https://orcid.org/0000-0002-0990-2268">https://orcid.org/0000-0002-0990-2268</a> )
<b>Competing interests</b>	No potential conflict of interest relevant to this article was reported.
<b>Funding sources</b> State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available.	This work was supported by grants from Korea University and the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry (iPET) through the High Value-Added Food Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (1545027002, RS-2021-IP321036).
<b>Acknowledgements</b>	Not applicable.
<b>Availability of data and material</b>	Upon reasonable request, the datasets of this study can be available from the corresponding author.
<b>Authors' contributions</b> Please specify the authors' role using this form.	Conceptualization: Kim SH, Kim JY, Park SM, Mok JY, Seo JH. Data curation: Kim JY. Formal analysis: Kim JY. Methodology: Kim SH, Choi YH. Software: Kim JY, Choi YH. Validation: Kim JY. Investigation: Choi YH. Writing - original draft: Kim JY. Writing - review & editing: Kim JY, Choi YH, Park SM, Mok JY, Seo JH, Kim SH.

<b>Ethics approval and consent to participate</b>	Animal experiments were approved by the Institutional Animal Care and Use Committee of Korea University (KUIACUC-2023-0076).
---	--

**CORRESPONDING AUTHOR CONTACT INFORMATION**

<b>For the corresponding author (responsible for correspondence, proofreading, and reprints)</b>	<b>Fill in information in each box below</b>
First name, middle initial, last name	Sae Hun Kim
Email address – this is where your proofs will be sent	<a href="mailto:saehkim@korea.ac.kr">saehkim@korea.ac.kr</a>
Secondary Email address	<a href="mailto:saehkim@gmail.com">saehkim@gmail.com</a>
Address	College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea
Cell phone number	82-10-9071-3055
Office phone number	82-2-3290-3055
Fax number	-

ACCEPTED

1 ***Weissella confusa* WiKim51 (Wilac D001) fermented mycelium extract attenuates joint**  
2 **inflammation through PGE2 regulation in collagen-induced arthritis rats**

3

4 **Running Title: Joint inflammation-attenuating effects of *Weissella confusa* WiKim51**  
5 **fermented mycelium extract**

6

7 Jae-Young Kim<sup>1,2</sup>, Yi Hyun Choi<sup>1</sup>, Sang Min Park<sup>3</sup>, Ji Ye Mok<sup>3</sup>, Jeong Hyun Seo<sup>3</sup>, and Sae  
8 Hun Kim<sup>1,2\*</sup>

9 <sup>1</sup> College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of  
10 Korea.

11 <sup>2</sup> Institute of Life Science and Natural Resources, Korea University, Seoul 02841, Republic of  
12 Korea.

13 <sup>3</sup> Pharmsville Co., Ltd., Seoul 06642, Republic of Korea

14

15 Author ORCIDs: Jae-Young Kim (0000-0003-1937-9535), Yi Hyun Choi (0009-0006-0513-  
16 1503), Sang Min Park (0000-0002-5599-233X), Ji Ye Mok (0009-0009-2542-0785), Jeong  
17 Hyun Seo (0000-0002-9197-4550), Sae Hun Kim (0000-0002-0990-2268)

18

19

20 **Corresponding author**

21 Prof. Sae Hun Kim, Ph.D.

22 Mailing address: College of Life Sciences and Biotechnology, Korea University, Seoul  
23 02841, Republic of Korea

24 Phone number: +82-2-3290-3055

25 Email address: [saehkim@korea.ac.kr](mailto:saehkim@korea.ac.kr)

26 **Abstract**

27 Rheumatoid arthritis (RA) is the state of joint inflammation, leading to cartilage and bone destruction.  
28 During rheumatoid arthritis progression, cyclooxygenase (COX) activity and its downstream  
29 production of prostaglandin E2 (PGE2) contribute to bone and cartilage erosion. WCF-ME was selected  
30 because its anti-inflammatory properties were confirmed *in vitro*. Therefore, this study aimed to  
31 evaluate the joint inflammation regulating capacities of *Weissella confusa* WiKim51 (Wilac D001)  
32 (WC), mycelium extract (ME), and WC-fermented ME (WCF-ME). In a collagen-induced arthritis  
33 (CIA) model, CIA-induced serum TNF $\alpha$  was normalized by WCF-ME treatment, while PGE2 was  
34 reduced by WC and WCF-ME treatment. ME had no effect in both serum markers. CIA-induced paw  
35 swelling and deformation was significantly lowered by WC and WCF-ME from the 21<sup>st</sup> day after  
36 immunization, while ME had no effect. Furthermore, knee joint gene expressions of *Il6* and *Mmp3* gene  
37 expressions were normalized by all treatments, while *Il1b* gene expression was normalized only in the  
38 WC group. *Mmp13* gene expressions were normalized by WC and WCF-ME, while ME had no  
39 significant difference. Spearman's correlation analysis showed that serum PGE2 was proportional to  
40 *Il6*, *Il1b*, and *Mmp13*. Overall, these results indicate that WC and WCF-ME ameliorated CIA-induced  
41 RA symptoms through inhibition of PGE2 activity, leading to reduced *Il6*, *Mmp3*, and *Mmp13*  
42 expressions in the knee. Therefore, WC and WCF-ME has potential as a novel RA treatment.

43  
44 **Keywords:** Rheumatoid Arthritis, *Weissella confusa*, Mycelium, Anti-inflammatory, PGE2, joint

45

## Introduction

46

47 Rheumatoid arthritis (RA) is the state of acute or chronic joint inflammation, resulting in  
48 cartilage and bone destruction. RA symptoms are treated through usage of drugs such as  
49 methotrexate (MTX), in which inhibit purine synthesis and subsequently induce cell apoptosis [1].  
50 However, long term MTX usage may cause adverse effects such as nausea, mucosal ulcers, and  
51 hepatotoxicity [2]. Thus, studies on treatments targeting different mechanisms are on-going.  
52 Nonsteroidal anti-inflammatory drugs (NSAIDs) treat RA symptoms through inhibition of  
53 cyclooxygenase (COX) activity and their downstream production of prostaglandin E2 (PGE2) [3].  
54 PGE2 and tumor necrosis factor alpha (TNF $\alpha$ ) are released by macrophages participating in bone and  
55 cartilage erosion [4]. Thus, various studies are being conducted to develop treatments that regulate the  
56 production of these inflammatory markers.

57 Mycelia have been used in folk medicine for their nutritional and medicinal properties. Recent  
58 studies support their therapeutic effects, suggesting that this may be due to their high levels of  
59 polysaccharides, proteins, and bioelements etc. In a previous report, supplementation of *Auricularia*  
60 *auricula-judae*, a saprophytic fungus that grows on rotted wood in forests, reduced levels of  
61 inflammatory mediators such as interleukin 6 (*Il6*), interleukin 1 beta (*Il1 $\beta$* ), and *Tnfa* in a mouse obesity  
62 model [5]. Supplementation of *Sparassis crispa*, a brown-rot fungus that grows on coniferous tree  
63 stumps, also showed inhibitory effects on pro-inflammatory mediators [6]. Thus, results suggest that  
64 mycelia have potential as immunoregulating agents. Mycelia refer to the fungal biomass, including  
65 hyphal structures, while mycelium extracts are concentrated forms obtained via solvent extraction,  
66 which enhance the accessibility and potential bioactivity of key compounds. In this study, we focused  
67 on mycelium extracts due to their demonstrated anti-inflammatory potential in preliminary in vitro tests.

68

69 Lactic acid bacteria are gram-positive, lactic acid-producing organisms that possess various  
70 health benefits. Major strains include probiotics—live microorganisms that confer health benefits to the  
71 host when administered in adequate amounts [7]. Among various probiotics, the *Lactobacillaceae*  
72 family is the most well-known and used in the probiotic industry [8]. *Lactobacillaceae* family strains

73 are involved in fermentation; they regulate microbial growth and the enzymatic conversion of food  
74 constituents, which in turn produces beneficial end-products, such as organic acids, bacteriocins, and  
75 peptides [9]. *Weissella*, a genus belonging to the *Lactobacillaceae* family, are known to exert host-  
76 beneficial effects such as anti-microbial, anti-inflammatory, and anti-cancer activity [10]. Moreover,  
77 *Weissella*-fermented *Asparagus cochinchinensis* showed higher anti-inflammatory effects than the non-  
78 fermented *Asparagus cochinchinensis*, indicating the potential of *Weissella*-fermentation in enhancing  
79 immunomodulatory effects of natural products [11]. Thus, *Weissella*-fermentation products may be a  
80 potent candidate for RA treatment through the regulation of inflammatory responses. Therefore, this  
81 study aimed to compare the RA attenuating effects of *Weissella confusa* WiKim51 (Wilac D001) (WC),  
82 mycelium extract (ME), and *Weissella confusa* WiKim51 (Wilac D001)-fermented mycelium extract  
83 (WCF-ME) in RA models. Our study introduces a novel perspective on the utilization of mycelium  
84 extracts as a treatment for RA, which has not been frequently addressed in previous studies. Moreover,  
85 our study aims to enhance functional properties of mycelium extracts through fermentation, and  
86 ultimately heighten the value of mycelium extracts as a food product.

## 88 **Materials and Methods**

### 89 **Materials**

90 Bacterial strain *Weissella confusa* WiKim51 (Wilac D001) (*W. confusa*), (99.73 % identity;  
91 accession no. LC063164.1) were obtained from Pharmsvile Co., Ltd. (Seoul, South Korea). 16s rRNA  
92 sequencing was performed by Macrogen (Seoul, South Korea) for strain identification. *W. confusa*  
93 WiKim51 was cultured for 24 h at 37 °C in Man, Rogosa, and Sharpe (MRS) broth (BD Co., Franklin  
94 Lakes, NJ, USA). All strains were subcultured three times prior use.

### 96 **Sample preparation**

97 *Auricularia auricula-judae* mycelium powder (Mush&, Jeonju, South Korea) and *Sparassis*  
98 *crispa* mycelium powder (Mush&, Jeonju, South Korea) were mixed [1:3 w/w], dissolved in distilled

99 water [1:10 w/v], and used for reflux extraction at 100 °C for 6 hr. The resulting extracts were added  
100 with minimal broth (glucose [1:25 w/v], peptone [1:100 w/v], sodium acetate 3H<sub>2</sub>O [1:200 w/v],  
101 magnesium sulfate 7H<sub>2</sub>O [1:10,000 w/v], manganese sulfate 4H<sub>2</sub>O [1:20,000 w/v], 5 mL tween 80  
102 [1:100 v/v], diammonium citrate [1:500 w/v], dipotassium phosphate [1:500 w/v]), and autoclaved  
103 (121 °C, 15 min). The resulting mixture was termed Mycelium Extract (ME). Thereafter, *W. confusa*  
104 WiKim51 (WC) culture was centrifuged at 10,800 × g for 3 min (VS-180Cfi, Vision Scientific Co.,  
105 Daejeon, Korea) and washed twice with phosphate-buffered saline (PBS). Next, the optical density of  
106 the harvested bacterial pellets at 600 nm was adjusted to 0.3; the pellets were added to ME (1:50 v/v)  
107 and incubated for 48 h. Sample preparations were done at 0 h, 24 h, and 48 h fermentation and spread  
108 on MRS agar plates (Kisan Bio) to assess bacterial growth. ME fermented with WC for 48 h was termed  
109 WCF-ME. Subsequently, WCF-ME was filtered using Whatman filter paper–Grade 3 (6µm)  
110 (Whatman™, Maidstone, United Kingdom), freeze dried, and kept at – 80 °C until use.

111

### 112 **Gas chromatography/mass spectrometry (GC/MS) instrumentation and** 113 **chromatographic condition**

114 Short chain fatty acid (SCFA) contents of ME and WCF-ME were determined using GC/MS,  
115 per the method described by Kim, Jang [9] with slight modifications. Briefly, 50mg of ME or WCF-  
116 ME samples were combined with 100 µL crotonic acid, 50 µL HCl, and 200 µL ether, and then  
117 homogenized and centrifuged at 1000 ×g for 10 min. Supernatants were transferred to vials and 16 µL  
118 N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (Sigma–Aldrich, USA) was added. After  
119 mixing, vials were sealed and heated at 80 °C for 20 min, and then kept in room temperature for 48 h.  
120 Samples were placed in a 6890N Network GC System (Agilent Technologies, California, USA) with a  
121 HP-5MS column (30 m, 0.25 mm, 0.25 µm) and 5973 Network Mass Selective Detector (Agilent  
122 Technologies, USA). Helium (99.9999% purity) was used as a delivery gas at a flow rate of 1.2 mL/min.  
123 The head pressure was 97 kPa and the split was 20:1. The inlet and transfer line temperatures were 250  
124 and 260 °C, respectively. The following temperature program was used: 60 °C (3 min), 60–120 °C (5 °C

125 min), 120–300 °C (20 °C min). One microliter of sample was injected with 30 min of run time. SCFA  
126 concentrations were qualified by comparing their peak areas with those of the standards.

127

## 128 **Cell culture**

129 MH7A human rheumatoid fibroblast-like synoviocytes were obtained from the RIKEN  
130 BioResource Research Center (BRC, Tsukuba, Japan). Cells were cultured in Dulbecco's Modified  
131 Eagle Medium (DMEM), high glucose (Gibco, Dublin, Ireland) with 10% fetal bovine serum (Hyclone,  
132 MA, USA), and 1% P/S (GE Healthcare). All cultures were incubated in a humid atmosphere (37 °C,  
133 5% CO<sub>2</sub>).

134

## 135 **Cell cytotoxicity assessment using the CCK-8 assay**

136 Cell cytotoxicity was measured by the cell counting kit-8 assay (CCK-8) (K1018, APEX BIO  
137 Corporation, USA) according to the manufacturer's instructions. MH7A cells were seeded at a density  
138 of  $3 \times 10^4$  cells/well in 48-well plates. After 24 h incubation, the cells were pre-treated with ME or  
139 WCF-ME dose-dependently (100, 200, 300, 500, 750, and 1000 µg/mL) and incubated for 24 h (37 °C,  
140 5 % CO<sub>2</sub>). Subsequently, the cells were treated with 200 µL of 10 % CCK-8 solution and incubated in  
141 the dark for 2 h. Eventually, absorbance was measured at 450 nm using the Epoch microplate  
142 spectrophotometer (BioTek, VT, USA), and the relative percentage of cell proliferation was calculated.

143

## 144 **Anti-inflammatory activity evaluation in MH7A Cells**

145 The gene expression of inflammation-related biomarkers was measured by RT-qPCR [12].  
146 MH7A cells were each seeded at a density of  $2 \times 10^5$  cells/well in 6-well plates. After 24 h incubation,  
147 cells were pre-treated with ME (750 µg/mL) and WCF-ME (750 µg/mL) diluted in DMEM and  
148 incubated for 18 h (37 °C, 5 % CO<sub>2</sub>). To stimulate inflammatory responses, 10 ng/mL of TNFα  
149 (PeproTech, USA) diluted with DMEM was added and incubated for 6 h (37 °C, 5 % CO<sub>2</sub>). RNA was  
150 extracted from the cells using TRIzol reagent (Thermo Fisher Scientific) following the manufacturer's  
151 protocol. The final RNA concentration and purity were determined by ultraviolet absorbance using a

152 NanoDrop spectrophotometer (BioTek, VT, USA). cDNA was synthesized using a cDNA reverse  
153 transcription kit (Thermo Fisher Scientific). Reverse transcription quantitative real-time PCR (RT-  
154 qPCR) was performed using the CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA,  
155 USA). Targeted gene expression was quantified using 2X Real-Time PCR Smart Mix (SolGent,  
156 Daejeon, South Korea). The mRNA expression levels of each target gene were analyzed and normalized  
157 to that of the housekeeping gene GAPDH. The primer sequences used in this study are listed in Table  
158 1.

159

### 160 **Animal model and design**

161 Animal experiments were approved by the Institutional Animal Care and Use Committee of  
162 Korea University (KUIACUC-2023-0076) and performed in accordance with the guidelines from the  
163 NIH Guide for the Care and Use of Laboratory Animals and the Animal Research: Reporting of *In Vivo*  
164 Experiments (ARRIVE) guidelines. Seven-week-old male Wistar rats (ORIENTBIO Inc., Sunnam,  
165 South Korea) were acclimated for one week at 25 °C under a 12 h light/dark cycle and given *ad libitum*  
166 access to food and water. Forty-two rats were randomly divided into six groups: Con [vehicle  
167 (phosphate buffered saline, PBS) treatment], CIA [immunization + vehicle (PBS) treatment], MTX  
168 [immunization + Methotrexate (0.2 mg/kg; Korea United Pharm. Inc., Seoul, South Korea)] treatment],  
169 WC [immunization + *W. confusa* WiKim51 ( $10^{10}$  CFU/kg) treatment], ME [mycelium extract (600  
170 mg/kg) treatment, and WCF-ME [immunization + *W. confusa* WiKim51 fermented-mycelium extract  
171 (600 mg/kg) treatment]. ME and WCF-ME dosages were selected based on previous studies reporting  
172 effective anti-inflammatory or metabolic regulatory activity of mycelium-derived substances in rodent  
173 models [5, 6]. After acclimatization, all groups except the Con group were immunized twice. Emulsions  
174 for immunization were prepared by mixing bovine type II collagen in 0.05 M acetic acid (2 mg/mL)  
175 (20022, Chondrex. Inc, Woodinville, USA) and Freund's Incomplete Adjuvant (IFA) (7002, Chondrex.  
176 Inc, Woodinville, USA) at a ratio of 1:1. The first immunization was conducted on the 7<sup>th</sup> day after  
177 acclimatization through a subcutaneous tail injection of 0.2 mL emulsion. The second immunization  
178 was conducted on the 14<sup>th</sup> day after acclimatization through a subcutaneous tail injection of 0.1 mL

179 emulsion. On the 21<sup>st</sup> day after acclimatization, rats in which the immunization model was not  
180 successfully established were eliminated, guaranteeing at least 5 rats in each group. On the 22<sup>nd</sup> day  
181 after acclimatization treatments were administered via oral gavage for four weeks. All treatment  
182 suspensions were prepared daily using PBS as the vehicle. Body weight, food intake, water intake, paw  
183 thickness, and arthritis scores were measured during this period. Arthritis severity was scored based on  
184 the criteria listed in Table 2 [13].

185 After all treatments, mice were fasted for 24 h, anesthetized by isoflurane–oxygen mixture  
186 inhalation (1.5-2.5 %; Hana Pharm, Sungnam, South Korea), and euthanized under isoflurane  
187 anesthesia by excising the heart. Blood samples were collected via cardiac puncture and centrifuged at  
188 13000 ×g for 15 min at 4 °C to extract serum, which was subsequently stored at -20 °C for a maximum  
189 of two weeks for further analysis. After excision, the knee joint and hind paw tissues were washed with  
190 phosphate buffered saline (PBS). One piece was fixed in 10 % neutral-buffered formalin (Sigma-  
191 Aldrich) for hematoxylin and eosin (H&E) staining, and the other was stored in RNAlater solution  
192 (Invitrogen, California, USA) at -80 °C for further analysis.

193

#### 194 **Serum analysis**

195 ELISA kits were used to measure serum TNF $\alpha$  (K0331196, Komabiotech, Korea) and PGE2  
196 (KGB004B, R&D systems, USA) according to the manufacturer's instructions.

197

#### 198 **Histological analysis**

199 At the end of the experiment, a histological analysis was performed on the hind paw joints of  
200 each mouse. Hind paw joints from each group were fixed in 10 % (v/v) formaldehyde, decalcified (RDO  
201 Gold, Apex Engineering Products Corporation, USA), and embedded in paraffin blocks using standard  
202 techniques. Further, 4–5  $\mu$ m sections were sliced and stained with H&E. Digital photomicrographs were  
203 taken from representative areas using a slide scanner (Easyscan Pro6, Motic, Hong Kong).

204

#### 205 **RNA extraction and RT-qPCR**

206 The knee joint tissues were homogenized using a tissue tear homogenizer (BioSpec, Oklahoma,  
207 USA). Total mRNA from the homogenized tissues was extracted using TRIzol reagent (15596018,  
208 Thermo Fisher Scientific) according to the manufacturer's instructions. Total RNA extracts mixed with  
209 30  $\mu$ L lithium chloride (LiCl) (AM9480, Invitrogen, USA) and incubated at -20 °C for 30 min for  
210 purification. Solutions were centrifuged at 13000  $\times g$  for 15 min at 4 °C to collect pellets, which were  
211 subsequently washed three times with 75 % ethanol to remove residual salts. RNA pellets were  
212 resuspended in diethyl pyrocarbonate (DEPC, Sigma-Aldrich, USA) for cDNA synthesis. The final  
213 RNA concentration and purity were determined by ultraviolet absorbance using a NanoDrop  
214 spectrophotometer (BioTek, VT, USA). Subsequent procedures were similar to those used to evaluate  
215 the anti-inflammatory activity in MH7A cells. The primer sequences used in this study are listed in  
216 Table 1.

217

## 218 **Statistical Analysis**

219 Statistical analyses were performed using the SPSS Statistics software (version 25.0; IBM,  
220 Armonk, NY, USA). One-way analysis of variance with Duncan's or Student's t-test was used to  
221 quantify the statistical differences between the mean values of the samples.  $P < 0.05$  was considered  
222 statistically significant. Correlation strength was interpreted based on the absolute value of Spearman's  
223  $\rho$  (rho), with  $|\rho| > 0.6$  considered a moderate to strong correlation. All figures were generated using  
224 GraphPad Prism 9.0 (GraphPad Software, La Jolla, CA, USA). Correlation-based analyses and  
225 visualizations were performed using R Studio (RStudio, Boston, MA, United States) and related  
226 packages such as dplyr, tibble, tidyr, magrittr, psych, corrplot, RcolorBrewer, and ggcorrplot.

227

228

## **Results**

229 **In vitro assessment of ME and WCF-ME based on secondary metabolite production and**  
230 **anti-inflammatory activity**

231 In vitro assessments of ME and WCF-ME were conducted to compare their compositional and  
232 functional characteristics (Fig. 1.). ME supplementation in bacterial growth medium had no effect on  
233 WC growth, indicating non-toxicity (Fig. 1a) ( $p < 0.05$ ). Although the most rapid bacterial growth was  
234 observed at 24 h, WC bacterial growth remained elevated at 48 h and exhibited significantly increased  
235 acetate concentration at this time point (Fig. 1b) ( $p < 0.05$ ), suggesting enhanced metabolic activity.  
236 Therefore, 48 h was selected as the optimal fermentation time to ensure both microbial activity and  
237 functional enhancement. Thus, WC-fermented ME at 48 h was selected as WCF-ME for further  
238 experiments.

239 The anti-inflammatory properties of WCF-ME were further evaluated with a  $\text{TNF}\alpha$ -induced  
240 inflammatory cell model. The optimal dosage for in vitro assays was selected based on cell viability  
241 measurements using the CCK-8 assay (Figs. 1c and d). ME and WCF-ME treatments of 1000  $\mu\text{g}/\text{mL}$   
242 reduced cell viability to levels lower than the control (0  $\mu\text{g}/\text{mL}$ ) ( $p < 0.05$ ). Treatments of 750  $\mu\text{g}/\text{mL}$   
243 ME and WCF-ME maintained cell viability at 95 % ( $p < 0.05$ ). As a healthy cell culture is considered  
244 to show 80–95 % cell viability [14], 750  $\mu\text{g}/\text{mL}$  was selected as the optimal dosage for in vitro anti-  
245 inflammatory assessments.

246 ME and WCF-ME were pre-treated in  $\text{TNF}\alpha$ -induced inflammatory MH7A cells to determine  
247 their in vitro anti-inflammatory potential. Both treatments showed lower gene expressions of *MMP3*,  
248 *MMP13*, and *IL1B* than the  $\text{TNF}\alpha$  only-treated group ( $p < 0.05$ ) (Figs. 1e–g). Notably,  $\text{TNF}\alpha$ -induced  
249 gene expression of *IL6* was lowered only by WCF-ME, while ME had no effect ( $p < 0.05$ ) (Fig. 1h).  
250 These results indicate that both ME and WCF-ME have anti-inflammatory potential, while WC-  
251 fermentation may enhance the anti-inflammatory abilities of WCF-ME to those greater than ME.

252

### 253 **Effects of WC, ME, and WCF-ME in growth parameters and serum biomarkers of an** 254 **CIA-induced arthritis rat model**

255 The in vivo effects of ME, WC, and WCF-ME treatments were evaluated in an CIA-induced  
256 arthritis rat model. CIA treatment reduced body weight and food intake, indicating induction of  
257 inflammation ( $p < 0.05$ ) (Figs. 2a and b). However, all treatments did not ameliorate CIA-induced loss

258 of body weight and food intake. All groups showed no difference in water intake (Figs. 2c). Moreover,  
259 CIA-injections elevated levels of serum inflammatory markers TNF $\alpha$  and PGE2 to those higher than  
260 the Con group ( $p < 0.05$ ) (Figs. 2d and e). Serum TNF $\alpha$  was normalized by MTX and WCF-ME  
261 treatment, while WC and ME had no effect ( $p < 0.05$ ). Serum PGE2 was normalized by MTX and WC  
262 ( $p < 0.05$ ), while WCF-ME showed reducing effects ( $p < 0.05$ ). Thus, results indicate that CIA-induced  
263 inflammation may be attenuated by WC and WCF-ME treatment.

264

### 265 **Effects of WC, ME, and WCF-ME on CIA-induced joint destruction**

266 Severity of joint destruction was evaluated through gross morphology and H&E-stained hind paw  
267 joints. CIA induced severe swelling and deformation in gross images (Fig. 3a). Furthermore, CIA  
268 induced cartilage destruction, synovium hyperplasia, and pannus formation in H&E-stained tissues, in  
269 which are evident symptoms of rheumatoid arthritis (Figs. 3b and c). MTX, WC, and WCF-ME  
270 attenuated these changes, suggesting protective effects on rheumatoid arthritis. Moreover,  
271 measurements of paw thickness and arthritis scores were conducted every three days after immunization  
272 to determine arthritis development. CIA-induced paw swelling was reduced by WC and WCF-ME from  
273 the 21<sup>st</sup> day after immunization. Arthritis scores of MTX, WC, and WCF-ME groups were significantly  
274 lower than the CIA group from the 21<sup>st</sup> day after immunization. Therefore, results indicate that WC and  
275 WCF-ME may have protective effects against CIA-induced rheumatoid arthritis.

276

### 277 **Effects of WC, ME, and WCF-ME on knee joint inflammation**

278 The effects of WC, ME, and WCF-ME on knee joint inflammation were evaluated using RT-  
279 qPCR (Fig. 4). Gene expression of *Il6*, *Il1b*, *Mmp3*, and *Mmp13* was increased in the CIA group ( $p <$   
280  $0.05$ ) (Figs. 4a–d). *Il6* and *Mmp3* gene expressions were normalized by all treatments ( $p < 0.05$ ). *Il1b*  
281 gene expression was normalized only in the WC group ( $p < 0.05$ ). *Mmp13* gene expressions were  
282 normalized by WC and WCF-ME, while ME had no significant difference ( $p < 0.05$ ). Thus, results  
283 indicate that WC and WCF-ME may ameliorate CIA-induced knee joint inflammation.

284 Spearman's correlation analysis was conducted to determine the relationship between serum  
285 ELISA and knee joint RT-qPCR results (Fig. 4e). Serum TNF $\alpha$  was positively correlated with knee  
286 joint *Il6* ( $\rho = 0.3717, p < 0.05$ ). Serum PGE2 was proportional to *Il6* ( $\rho = 0.4557, p < 0.05$ ), ( $\rho = 0.4562,$   
287  $p < 0.05$ ), and *Mmp13* ( $\rho = 0.4938, p < 0.05$ ). These results indicate that WC and WCF-ME may have  
288 altered levels of serum inflammation markers, thereby subsiding knee joint inflammation marker  
289 expressions in the host.

290

291

## Discussion

292 In this study, we investigated the potential benefits of WC, ME, and WCF-ME as RA  
293 treatments in a CIA-induced rat model. Pathogenesis of RA remain unclear. However, major RA  
294 treatments such as NSAIDs exert their effects through COX inhibition, which leads to the reduction of  
295 PGE2 [3]. Inflammatory stimuli such as TNF $\alpha$  can activate PGE2-mediated inflammatory responses,  
296 in which induces MMP3 and MMP13 expression [15]. MMPs are zinc-dependent endopeptidases that  
297 can cause cartilage extracellular matrix degradation when existing in excess amounts. In previous  
298 reports, MMP3 and MMP13 increase in arthritis patients, suggesting that MMPs play a critical role in  
299 cartilage destruction [16]. Therefore, in this study, we aimed to select treatments with anti-inflammatory  
300 potential to attenuate PGE2-mediated cartilage destruction.

301 Our in vitro data showed that *Weissella*-fermentation of ME increased acetate concentrations  
302 (Fig. 1b). In a previous report, administration of acetate prior to the onset of CIA-induced arthritis in  
303 mice improved arthritic symptoms [17]. Acetate, a short chain fatty acid, suppresses inflammation  
304 through inhibition of NLRP3 inflammasome activity, consequently leading to NLRP3 degradation [18].  
305 NLRP3 expression is positively correlated with arthritis severity in various arthritis models such as CIA  
306 or antigen-induced arthritis models, implying its involvement in RA pathogenesis [19]. Therefore,  
307 fermentation may enhance the bioactivity of ME by increasing acetate content, thereby improving its  
308 therapeutic potential.

309 Consistently, only WCF-ME suppressed *IL6* gene expression, while both ME and WCF-ME  
310 reduced gene expressions of *MMP3*, *MMP13*, and *IL1B* in TNF $\alpha$ -induced inflammatory MH7A cells

311 (Figs. 1e-h). IL6 has a crucial role in RA pathogenesis that promotes osteoclast activation, neutrophil  
312 recruitment, and B cell-mediated autoimmunity [20]. Thus, the inhibitory effects of WCF-ME on *IL6*  
313 gene expression highlights its superior potential in modulating core pathogenic pathways in RA.

314 Our in vivo study showed that MTX and WCF-ME suppressed systemic TNF $\alpha$  and PGE2  
315 levels, whereas WC selectively reduced PGE2 (Figs. 2d and e). These findings imply that WC and  
316 WCF-ME exert anti-inflammatory effects via distinct mechanisms. Given that ME alone showed no  
317 significant effect, this supports the enhanced bio-efficacy imparted by fermentation. Furthermore,  
318 clinical indicators such as paw thickness and arthritis scores were significantly improved by WC and  
319 WCF-ME, but not by ME, indicating therapeutic enhancement throughout fermentation (Fig. 3).  
320 Histological analysis revealed that MTX, WC, and WCF-ME alleviated CIA-induced joint destruction,  
321 including pannus formation and cartilage erosion. Molecular analyses further confirmed that CIA-  
322 induced expression of *Il1b*, *Il6*, and *Mmp13* in knee joints was reduced by WC and WCF-ME. Notably,  
323 correlation analysis revealed that serum PGE2 was positively correlated with *Il1b*, *Il6*, and *Mmp13*  
324 expression, implying that the therapeutic effects of WC and WCF-ME may be mediated through  
325 systemic regulation of PGE2 [21, 22].

326 Taken together, our findings suggest that WC and WCF-ME mitigate RA progression by  
327 inhibiting PGE2 and downstream inflammatory mediators, thereby protecting joint integrity. This is the  
328 first report demonstrating the enhanced anti-inflammatory activity of ME via *Weissella*-fermentation in  
329 the context of RA.

330 In conclusion, WC and WCF-ME ameliorated CIA-induced RA symptoms by modulating key  
331 inflammatory pathways, notably through PGE2 suppression and downstream cytokine regulation.  
332 These findings suggest that fermentation enhances the functional properties of ME and that WC and  
333 WCF-ME hold promise as functional food ingredients or complementary therapies for RA. Nonetheless,  
334 limitations such as the use of a single animal model and lack of human validation must be addressed.  
335 Future studies should include long-term safety evaluation, mechanistic exploration of bioactive  
336 metabolites, and clinical validation.

337

338

ACCEPTED

339

## **Competing Interests**

340 No potential conflict of interest relevant to this article was reported.

341

342

## **Acknowledgments**

343 This work was supported by grants from Korea University and the Korea Institute of Planning and  
344 Evaluation for Technology in Food, Agriculture, Forestry (iPET) through the High Value-Added Food  
345 Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs  
346 (MAFRA) (1545027002).

347

348

## **Ethics approval**

349 Animal experiments were approved by the Institutional Animal Care and Use Committee of Korea  
350 University (KUIACUC-2023-0076).

351

352

ACCEPTED

## References

- 354 1. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. *Joint*  
355 *Bone Spine*. 2019;86(3):301-7. <https://doi.org/10.1016/j.jbspin.2018.07.004>
- 356 2. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A  
357 systematic review. *European Journal of Medicinal Chemistry*. 2018;158:502-16.  
358 <https://doi.org/10.1016/j.ejmech.2018.09.027>
- 359 3. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of  
360 rheumatoid arthritis. *Journal of Clinical Investigation*. 2002;110(5):651-8.  
361 <https://doi.org/10.1172/JCI15528>
- 362 4. Shabbir A, Shahzad M, Ali A, Zia-ur-Rehman M. Anti-arthritis activity of N'-[(2,4-  
363 dihydroxyphenyl)methylidene]-2-(3,4-dimethyl-5,5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-  
364 1(4H)-yl)acetohydrazide. *European Journal of Pharmacology*. 2014;738:263-72.  
365 <https://doi.org/10.1016/j.ejphar.2014.05.045>
- 366 5. Liu Q, Ma R, Li S, Fei Y, Lei J, Li R, et al. Dietary Supplementation of *Auricularia auricula-judae*  
367 Polysaccharides Alleviate Nutritional Obesity in Mice via Regulating Inflammatory Response and  
368 Lipid Metabolism. *Foods*. 2022;11(7). <https://doi.org/10.3390/foods11070942>
- 369 6. Wang Z, Liu J, Zhong X, Li J, Wang X, Ji L, et al. Rapid characterization of chemical components  
370 in edible mushroom *sparassis crispa* by UPLC-Orbitrap MS analysis and potential inhibitory  
371 effects on allergic rhinitis. *Molecules*. 2019;24(16). <https://doi.org/10.3390/molecules24163014>
- 372 7. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document:  
373 The international scientific association for probiotics and prebiotics consensus statement on the  
374 scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology and Hepatology*.  
375 2014;11(8):506-14. <https://doi.org/10.1038/nrgastro.2014.66>
- 376 8. Lee CS, Kim BK, Lee IO, Park NH, Kim SH. Prevention of bone loss by using *Lactobacillus*-  
377 fermented milk products in a rat model of glucocorticoid-induced secondary osteoporosis. *Int*  
378 *Dairy J*. 2020;109. <https://doi.org/10.1016/j.idairyj.2020.104788>
- 379 9. Kim JY, Jang S, Song HJ, Lee S, Cheon S, Seo EJ, et al. *Sargassum horneri* extract fermented by  
380 *Lactiplantibacillus pentosus* SH803 mediates adipocyte metabolism in 3T3-L1 preadipocytes by  
381 regulating oxidative damage and inflammation. *Scientific Reports*. 2024;14(1).  
382 <https://doi.org/10.1038/s41598-024-65956-8>
- 383 10. Ahmed S, Singh S, Singh V, Roberts KD, Zaidi A, Rodriguez-Palacios A. The *Weissella* Genus:  
384 Clinically Treatable Bacteria with Antimicrobial/Probiotic Effects on Inflammation and Cancer.  
385 *Microorganisms*. 2022;10(12). <https://doi.org/10.3390/microorganisms10122427>

- 386 11. Lee HA, Song BR, Kim HR, Kim JE, Yun WB, Park JJ, et al. Butanol extracts of asparagus  
387 cochinchinensis fermented with weissella cibaria inhibit iNOS-mediated COX-2 induction  
388 pathway and inflammatory cytokines in LPS-stimulated RAW264.7 macrophage cells.  
389 Experimental and Therapeutic Medicine. 2017;14(5):4986-94.  
390 <https://doi.org/10.3892/etm.2017.5200>
- 391 12. Kim JY, Lee S, Kim G, Shin HJ, Lee EJ, Lee CS, et al. Ameliorating effect of 2'-Fucosyllactose  
392 and 6'-Sialyllactose on lipopolysaccharide-induced intestinal inflammation. J Dairy Sci. 2024.  
393 <https://doi.org/10.3168/jds.2024-24325>
- 394 13. Poutoglidou F, Pourzitaki C, Manthou ME, Samoladas E, Saitis A, Malliou F, et al. Infliximab  
395 prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis  
396 rat model. Inflammopharmacology. 2021;29(3):661-72. <https://doi.org/10.1007/s10787-021-00815-w>
- 398 14. Segeritz CP, Vallier L. Cell Culture: Growing Cells as Model Systems In Vitro. Basic Science  
399 Methods for Clinical Researchers. 2017. p. 151-72. <https://doi.org/10.1016/B978-0-12-803077-6.00009-6>
- 401 15. Jiang X, Renkema H, Pennings B, Pecheritsyna S, Schoeman JC, Hankemeier T, et al. Mechanism  
402 of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-  
403 1-mediated PGE2 biosynthesis by sonlicromanol's metabolite KH176m. Scientific Reports.  
404 2021;11(1). <https://doi.org/10.1038/s41598-020-79466-w>
- 405 16. Sirikaew N, Chomdej S, Tangyuenyong S, Tangjitjaroen W, Songird C, Thitaram C, et al.  
406 Proinflammatory cytokines and lipopolysaccharides up regulate MMP-3 and MMP-13 production  
407 in Asian elephant (*Elephas maximus*) chondrocytes: Attenuation by anti-arthritic agents. BMC  
408 Veterinary Research. 2019;15(1). <https://doi.org/10.1186/s12917-019-2170-8>
- 409 17. Yao Y, Cai X, Zheng Y, Zhang M, Fei W, Sun D, et al. Short-chain fatty acids regulate B cells  
410 differentiation via the FFA2 receptor to alleviate rheumatoid arthritis. British Journal of  
411 Pharmacology. 2022;179(17):4315-29. <https://doi.org/10.1111/bph.15852>
- 412 18. Xu M, Jiang Z, Wang C, Li N, Bo L, Zha Y, et al. Acetate attenuates inflammasome activation  
413 through GPR43-mediated Ca<sup>2+</sup>-dependent NLRP3 ubiquitination. Experimental and Molecular  
414 Medicine. 2019;51(7). <https://doi.org/10.1038/s12276-019-0276-5>
- 415 19. Yin H, Liu N, Sigdel KR, Duan L. Role of NLRP3 Inflammasome in Rheumatoid Arthritis.  
416 Frontiers in Immunology. 2022;13. <https://doi.org/10.3389/fimmu.2022.931690>
- 417 20. Srirangan S, Choy EH. The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis.  
418 Therapeutic Advances in Musculoskeletal Disease. 2010;2(5):247-56.  
419 <https://doi.org/10.1177/1759720X103783>

- 420 21. Jenei-Lanzl Z, Meurer A, Zaucke F. Interleukin-1 $\beta$  signaling in osteoarthritis – chondrocytes in  
421 focus. *Cellular Signalling*. 2019;53:212-23. <https://doi.org/10.1016/j.cellsig.2018.10.005>
- 422 22. Wang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces interleukin-6 expression in human  
423 chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF- $\kappa$ B  
424 activation. *American Journal of Physiology - Cell Physiology*. 2010;298(6):C1445-C56.  
425 <https://doi.org/10.1152/ajpcell.00508.2009>

426

ACCEPTED

427

## Tables

428 **Table 1.** Primer sequences used in RT-qPCR

Model	Gene	Sequence	Tm (°C)
Human	<i>IL6</i>	F: 5'- CCT GAC CCA ACC ACA AAT GC -3'	64.5
		R: 5'- ATC TGA GGT GCC CAT GCT AC -3'	
	<i>IL1B</i>	F: 5'- CCT GTC CTG CGT GTT GAA AGA -3'	57
		R: 5'- GGG AAC TGG GCA GAC TCA AA -3'	
	<i>MMP3</i>	F: 5'- CTG GAC TCC GAC ACT CTG GA -3'	55
		R: 5'- CAG GAA AGG TTC TGA AGT GAC C -3'	
	<i>MMP13</i>	F: 5'- CAA GAT GCG GGG TTC CTG AT -3'	63.3
		R: 5'- AAT GCC ATCGTGAAGTCTGGT -3'	
	<i>GAPDH</i>	F: 5'- TCA CCA GGG CTT GCT TTT AAC -3'	55
		R: 5'- AAT GAA GGG GTC ATT GAT GG -3'	
Rat	<i>Il6</i>	F: 5'- TCC TAC CCC AAC TTC CAA TGC TC -3'	63.3
		R: 5'- TTG GAT GGT CTT GGT CCT TAG CC -3'	
	<i>Il1b</i>	F: 5'- CAC CTC TCA AGC AGA GCA CAG -3'	65
		R: 5'- GGG TTC CAT GGT GAA GTC AAC -3'	
	<i>Mmp3</i>	F: 5'- ATC CCT CTA TGG ACC TCC CAC -3'	59
		R: 5'- AAC AAG ACT TCT CCC CGC AG -3'	
	<i>Mmp13</i>	F: 5'- GCG GTT CAC TTT GAG GAC AC -3'	63.3
		R: 5'- TAT GAG GCG GGG ATA GTC TTT -3'	
	<i>Actb</i>	F: 5'- AAG TCC CTC ACC CTC CCA AAA G -3'	65
		R: 5'- AAG CAA TGC TGT CAC CTT CCC -3'	

429

430 Tm: Annealing Temperature; *IL6*, *Il6*: interleukin 6; *IL1B*, *Il1b*: interleukin 1 beta; *MMP3*, *Mmp3*: matrix  
 431 metalloproteinase 3; *MMP13*, *Mmp13*: matrix metalloproteinase 13; *GAPDH*: glyceraldehyde-3-phosphate  
 432 dehydrogenase; *Actb*: beta-actin

433

434

435


436 **Table 2.** Arthritis Severity Scoring Criteria

Score	Joint Involvement
0	No evidence of erythema or swelling
1	Minimal erythema and swelling affecting ankle joint or mid-foot
2	Minimal erythema and swelling extending from ankle joint to mid-foot
3	Moderate erythema and swelling affecting the ankle joint, the mid-foot and the metatarsal joints
4	Severe erythema and swelling affecting the ankle joint, the mid-foot, the metatarsal joints and the digits

437


ACCEPTED

**Fig 1.**




**Fig 1.** In vitro assessment of *W. confusa* WiKim51 (Wilac D001)-fermented Mycelium Extract. (a) Bacterial growth of *W. confusa* WiKim51 (Wilac D001) in growth media supplemented with ME for 48h. (b) Acetate content in ME and WCF-ME. Viability of MH7A cells pretreated with different concentrations (0, 100, 200, 300, 500, 750, 1000 µg/mL) of (c) ME and (d) WCF-ME. Effects of ME and WCF-ME on gene expressions of inflammation related markers (e) *MMP3*, (f) *MMP13*, (g) *IL1B*, and (h) *IL6* in TNFα-treated MH7A cells. Results are expressed as mean ± SE ( $n = 3$ ). <sup>abcd</sup>Results in the same series with different lowercase superscript letters are significantly different ( $p < 0.05$ , one-way ANOVA); \* $p < 0.05$  ( $t$ -test ME vs. WCF-ME).

Fig 2.




**Fig 2.** Effects of WC, ME, and WCF-ME in growth parameters and serum biomarkers of an CIA-induced arthritis rat model. (a) Body weight. (b) Food intake. (c) Water intake. Serum levels of (d) TNF $\alpha$  and (e) PGE2. Data are expressed as the mean  $\pm$  SE ( $n = 5$ ). <sup>abc</sup>Means in the same series with different lowercase superscript letters are significantly different ( $p < 0.05$ , one-way ANOVA); \*\* $P < 0.01$ , \* $P < 0.05$  ( $t$ -test CIA vs. Each treatment).

**Fig 3.**



**Fig 3.** Effects of WC, ME, and WCF-ME on CIA-induced arthritis symptoms. Representative images of (a) gross morphology (scale bar: 1 cm) and H&E-stained hind paw joints (b) magnification: 40 ×, scale bar: 1000 μm; (c) magnification: 160 ×, scale bar: 1000 μm. The black box represents the area of magnification in the corresponding figure below. (d) Paw thickness. (e) Arthritis Scores. Data are expressed as the mean ± SE ( $n = 5$ ). \*\*\* $p < 0.001$ , \* $p < 0.05$  ( $t$ -test CIA vs. Each treatment).

**Fig 4.**



**Fig 4.** Effects of WC, ME, and WCF-ME on knee joint inflammation. Gene expressions of knee joint (a) *Il6*, (b) *Il1b*, (c) *Mmp3*, and (d) *Mmp13*. Spearman's correlation analysis of serum TNF $\alpha$  and PGE2 concentrations; and knee joint *Il6*, *Il1b*, *Mmp3*, and *Mmp13* gene expressions. Data are expressed as the mean  $\pm$  SE ( $n = 5$ ). <sup>abc</sup>Mean values in the same series with different lowercase letters are significantly different ( $p < 0.05$ , one-way ANOVA); \*\*\* $p < 0.001$ , \* $p < 0.05$ ).